Since these compounds possess higher affinity than the natural kinase substrate, ATP for the ATP-binding pocket in EGFR, they competitively inhibit the tyrosine kinase activity of the mutant receptor, thus blocking downstream signalling which in turn leads to inhibition of tumour cell growth. This evidence concerns the gene EGFR and neoplasm.